AB122 Controls Disease in Half of Solid Tumor Patients in Phase 1 Trial

AB122 Controls Disease in Half of Solid Tumor Patients in Phase 1 Trial
A potential antibody treatment called AB122 enabled tumor reduction and stable disease in half of patients with ovarian cancer and other types of advanced tumors, according to early results of an Arcus Biosciences Phase 1 trial. The findings from a small number of patients also revealed that AB122 benefits were similar to that of the approved therapies

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *